Last updated
Twist Bioscience: Capital Raising
Twist Bioscience priced a $300 million stock offering at $96 per share, indicating successful capital raise in public markets.
Source: Seeking Alpha — Market Currents
The leadership read
Twist Bioscience's raise resets the leadership agenda more than the balance sheet. Capital into Biotech & Pharma buys room to build senior operating and commercial bench strength ahead of scale. The near-term tilt favours operators who have scaled before; the appointments that follow say more than the announcement did across Americas.
Market context: MitchelLake's Talent Market Index sits at 104 (Hot), down 1.9 on the prior month; Americas hiring signal is running rising (+2.1pts).
Twist Bioscience: 2 signals in the last 90 days — above the Biotech & Pharma median of 1 across 24 tracked companies; 0.1% of MitchelLake's Americas signal flow; 2 tracked across 44 days.
MitchelLake in this thematic
Also at Twist Bioscience →
More signals across Biotech & Pharma
Capital Raising · Americas
Ratio Therapeutics →Ratio Therapeutics closed a Series C funding round of $70M for radiopharmaceutical trials, led by existing investors Duquesne Family Office and Bristol Myers Squibb, with new investor participation.
Capital Raising · Americas
BridgeBio →BridgeBio secured funding to support drug launch; United Airlines made an investment into the cell therapy space
Capital Raising · Americas
Sana Biotechnology, Inc. →Schedule 13G filing indicates potential significant ownership change or investment activity
Ma Activity · Americas
Biogen →Biogen completed acquisition of RayThera Inc., with the acquired company's lead program now in Phase 1 development.
Ma Activity · Americas
Teva Pharmaceuticals →Federal judge approved $35M settlement with healthcare funds over allegations Teva delayed generic versions of asthma inhalers, causing higher prices
Leadership Change · Americas
Flagship Pioneering →Flagship Pioneering, a scientific innovation engine, appointed two Executive Partners: Fidah Alsagoff (Head of Global Initiatives) and Maggie Sahlman (Head of Fundraising and Investor Relations).
Intelligence powered by Autonodal ↗